Ali Razaghi

Ali Razaghi

Postdoctoral Researcher
Visiting address: Alfred Nobels allé 8, plan 8, 14152
Postal address: H5 Laboratoriemedicin, H5 Patologi Björnstedt, 141 52 Huddinge

About me

  • A senior postdoctoral researcher with a speciality in Cancer Therapeutics, Medical Biotechnology and Immunotherapy. As a member of the research community of Karolinska Institute, one of the foremost global centres of medical science, Ali's research focuses on ground-breaking translational medicine using selenium-based chemotherapy and cytokine therapy approaches from pre-clinical stage to clinical trials in order to develop a more efficient treatment for benefiting cancer patients.

    Education
    Post Doctorate Diploma: Karolinska Institute (Stockholm, Sweden)
    PhD: James Cook University, Queensland, Australia
    MSc: University of Gothenburg (Göteborg, Sweden) and Leibniz University of Hanover (Hanover, Germany)
    Certificate in Advanced Cancer Biology, Johns Hopkins University, MD, USA

Research

  • The main objective of my studies is to investigate how selenotherapy (selenium-based chemotherapeutics) in combination with cytokine therapy can benefit cancer patients by enhancing the efficacy and lowering the side effects of treatments.

    My main specific research scopes are included:

    To explore and develop selenium-based chemotherapy particularly for pancreatic and liver cancers. Selenium-based compounds are potent chemotherapeutic agents eradicating a wide variety of tumour cells in low-dosage showing limited side-effects.
    To further advance the use of cytokine therapy in cancer immunotherapy. Cytokine therapy was the standard of care for treatment of many cancers from the 1980s onwards
  • hence, my approach is to utilize pro-inflammatory cytokines in a combinational regimen with chemotherapy to enhance the efficacy of treatments.




    My main research interests are included but not limited to:

    Designing and optimizing combinational treatments of cytokine therapy and selenotherapy for cancer
    Utilizing ex-vivo organotypic models of surgical specimen cancer tissues for screening new cancer treatments
    Implementing bioinformatic based techniques such as metagenomics and meta-analysis methods to explore novel markers and targets for the treatment of cancer
    Improving the enzymatic activity of therapeutic proteins using mutagenesis techniques
    Discovery and assessment of novel cancer therapeutics particularly selenium-based compounds
    Enhancing the efficacy of biopharmaceutical using genetic engineering e.g. by improving glycosylation

Articles

All other publications

News from KI

Events from KI